0013342 2022 RIV US eng J
Kaštánková, Iva - Štach, Martin - Žižková, Hana - Ptáčková, Pavlína - Šmilauerová, Kristýna - Mucha, Martin - Šroller, Vojtěch - Otáhal, Pavel^G
Enzymatically produced piggyBac transposon vectors for efficient non-viral manufacturing of CD19-specific CAR T cells.
Molecular therapy-methods & clinical development. Vol. 23, no. [December] (2021), s. 119-127. ISSN 2329-0501
Grant: Ministerstvo zdravotnictví 19-08-00147
Institucionální podpora: RVO:00023736
Klíčová slova: CD19 antigen * chimeric antigenic receptor * piggyBac transposon
Cite Score: 8.400, rok: 2021; SJR: 1.819, rok: 2021; IF: 5.849, rok: 2021
DOI: 10.1016/j.omtm.2021.08.006

Anotace: The piggyBac transposon system provides a non-viral alternative for cost-efficient and simple chimeric antigen receptor (CAR) T cell production. The generation of clinical-grade CAR T cells requires strict adherence to current good manufacturing practice (cGMP) standards. Unfortunately, the high costs of commonly used lentiviral or retroviral vectors limit the manufacturing of clinical-grade CAR T cells in many non-commercial academic institutions. Here, we present a manufacturing platform for highly efficient generation of CD19-specific CAR T cells (CAR19 T cells) based on co-electroporation of linear DNA transposon and mRNA encoding the piggyBac transposase.